Cipla has doubled production of COVID-19 medication remdesivir to help meet ‘unprecedented demand’ as the country battles a massive second wave of infections. India has overtaken Brazil as the world’s second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1929.00 |
| Dr. Reddys Labs. | 1244.85 |
| Cipla | 1439.65 |
| Zydus Lifesciences | 1148.95 |
| Lupin | 2495.30 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: